Primary navigation

    Trokendi XR

    Drug - Trokendi XR™ (topiramate capsule, extended-release) [Supernus Pharmaceuticals Inc.]

    June 2017

    Therapeutic area - Antiepileptics

    Approval criteria

    • is 6 years of age or older AND
    • Patient has one of the following diagnoses: partial onset seizures; primary generalized tonic/clonic seizures; Lennox-Gastaut syndrome AND
    • Patient has had a two-month trial of immediate-release topiramate OR
    • Patient is 12 years of age or older AND
    • Patient is prescribed Trokendi XR for prophylaxis of migraine headache AND
    • Patient has had a two-month trial of immediate-release topiramate 

    Quantity limit

    • If approved for qualified seizure disorder diagnosis
      • 200mg:  68 capsules per 34 days
      • 25mg, 50mg, 100mg:  102 capsules per 34 days
    • If approved for qualified migraine headache prophylaxis diagnosis
      • 25mg, 50mg:  68 capsules per 34 days
      • 100 mg capsules:  34 capsules per 34 days

    Additional information

    Trokendi XR™ is only indicated for treatment of specific seizure disorders and for prophylaxis of migraine headache. Appropriate diagnosis of seizures will be required for approval; use in neuralgia or bipolar disorder will not be approved.

    Questions?

    MHCP Provider Call Center 651-431-2700 or 800-366-5411

    back to top